Genmab A/S ADS (GMAB) Earnings Date & Reports

Key Takeaways

• Third-quarter revenue rose 16% year over year to $1,187 million, essentially in line with the roughly $1,200 million consensus estimate.
• Operating profit of $431 million beat expectations by about 22%, while net income of $342 million came in well above the consensus of roughly $219 million.
• Royalty revenue climbed to $991 million, powered by 19% growth in DARZALEX and continued strength from Kesimpta.
• Global net sales of EPKINLY/TEPKINLY jumped 47% to $491 million in the first nine months of 2026.
• Genmab maintained its full-year 2026 guidance and now expects revenue to land toward the upper end of its $4,325–$4,525 million range.
• Three positive Phase 3 readouts announced after quarter-end support potential regulatory submissions and launches in 2027.
• For more on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore Tickeron's dedicated pages for deeper, data-driven coverage.
• Discover Trending AI Robots to see how automated, AI-driven strategies are scanning the market for emerging opportunities.

Earnings Context and Why It Matters

Genmab's third-quarter report carries outsized weight for investors because the Danish biotechnology company is transitioning from a royalty-heavy model into a multi-product oncology franchise. Royalties from blockbusters like DARZALEX and Kesimpta still anchor the top line, but growth is increasingly coming from Genmab's own marketed therapy EPKINLY and its maturing late-stage pipeline. The quarter also follows a busy period marked by the integration of Merus, which added acquisition-related costs. With pivotal data readouts now in hand, this report offers a clearer view of whether Genmab can convert its pipeline momentum into sustained, diversified revenue growth.

Reported Results

Genmab reported third-quarter 2026 revenue of $1,187 million, up 16.1% from $1,022 million in the prior-year period and slightly below the Bloomberg consensus of $1,200 million. Royalty revenue reached $991 million, compared with $841 million a year earlier, driven primarily by higher net sales of DARZALEX and Kesimpta.

Operating profit came in at $431 million, exceeding the consensus estimate of roughly $352 million by about 22%, though it was down from $459 million in the same quarter last year. Net income was $342 million, a decline from $401 million a year ago but significantly ahead of the roughly $219 million analysts had anticipated. Basic earnings per share (EPS) were $5.58, down from $6.51 in the prior-year quarter, while diluted EPS were $5.51 versus $6.46.

For the first nine months of 2026, revenue rose 22% to $3,238 million, while operating profit dipped to $986 million from $1,007 million a year earlier. Genmab reiterated its full-year 2026 guidance, targeting revenue of $4,325–$4,525 million and adjusted operating profit of $1,065–$1,385 million, with management indicating revenue is expected to finish in the upper part of that range.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are tracking names like Genmab, the AI Screener can be a practical way to surface comparable biotech opportunities.

Market Reaction and Investor Sentiment

Genmab's American depositary receipts (ADRs) slipped roughly 2% on the day despite the operating-profit and net-income beats. The muted reaction likely reflects revenue arriving slightly below consensus, alongside a sharp rise in operating expenses as the company invests heavily in its pipeline and launch-readiness efforts. Net income also fell year over year, pressured by higher research and development costs and acquisition-related charges tied to the Merus integration. Still, investors appeared to focus on the positive Phase 3 readouts for epcoritamab, Rina-S, and petosemtamab, which reinforce the company's longer-term growth narrative.

Forward Outlook and Key Factors to Monitor

Following this report, the primary story is Genmab's late-stage pipeline. After quarter-end, the company announced positive Phase 3 results across three assets: epcoritamab in frontline diffuse large B-cell lymphoma (DLBCL), Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Management said these results support multiple regulatory submissions and potential product launches in 2027.

Investors should watch how quickly Genmab advances these regulatory discussions and whether the data translate into approvals. The company reiterated ambitious peak-sales targets of more than $3 billion for EPKINLY, more than $2 billion for Rina-S, and a multibillion-dollar opportunity for petosemtamab, including $1 billion in petosemtamab sales by 2029.

Cost discipline will also matter. Genmab expects fourth-quarter operating expenses to rise significantly as it scales manufacturing, clinical development, and launch preparation. Finally, the eventual expiration of DARZALEX royalties remains a long-term consideration, making the successful commercialization of Genmab's own products a key focus for the years ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations